Mereo BioPharma (MREO) Research & Development (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Research & Development of $4.7 million for Q1 2026, up 20.79% year-over-year from $3.9 million in Q1 2025, and up 13.21% quarter-over-quarter from $4.2 million in Q4 2025.
Mereo BioPharma (MREO) Research & Development (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Research & Development for 4 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 20.79% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $18.6 million (down 10.95% YoY), while the FY2025 annual figure was $17.8 million, down 15.12% from the prior year.
- Research & Development climbed to $4.7 million in Q1 2026 per MREO's latest filing, from $4.2 million in the prior quarter.
- Across five years, Research & Development topped out at $8.8 million in Q4 2024 and bottomed at $3.2 million in Q3 2024.
- Historically, Research & Development has averaged $4.7 million across 4 years, with a median of $4.3 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development soared 83.62% — and 2025, when it tumbled 52.47%.
- Mereo BioPharma's Research & Development stood at $4.8 million in 2023, then jumped by 83.62% to $8.8 million in 2024, then sank by 52.47% to $4.2 million in 2025, then rose by 13.21% to $4.7 million in 2026.
- Business Quant data shows MREO's Research & Development at $4.7 million in Q1 2026, $4.2 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 97.90 Mn |
| 10 | Mereo BioPharma | 47.54 Mn | 47.54 Mn | - | 1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Mar 31, 2026 | 4.75 Mn |
| Dec 31, 2025 | 4.19 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 5.37 Mn |
| Mar 31, 2025 | 3.93 Mn |
| Dec 31, 2024 | 8.82 Mn |
| Sep 30, 2024 | 3.17 Mn |
| Jun 30, 2024 | 4.95 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Dec 31, 2023 | 4.80 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Jun 30, 2023 | 3.71 Mn |
| Mar 31, 2023 | 5.31 Mn |